Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study.

Tumlin JA, Roy-Chaudhury P, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and Committees.

BMC Nephrol. 2019 Mar 5;20(1):80. doi: 10.1186/s12882-019-1212-6.

2.

Proteinuria in Nephrotic Syndrome: Mechanistic and Clinical Considerations in Optimizing Management.

Tumlin JA, Campbell KN.

Am J Nephrol. 2018;47 Suppl 1:1-2. doi: 10.1159/000481632. Epub 2018 May 31. No abstract available.

3.

Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Campbell KN, Tumlin JA.

Am J Nephrol. 2018;47 Suppl 1:14-29. doi: 10.1159/000481634. Epub 2018 May 31.

4.

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.

Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators.

Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092.

5.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

6.

Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.

Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and committees.

Kidney Int. 2018 Apr;93(4):941-951. doi: 10.1016/j.kint.2017.11.019. Epub 2018 Feb 12.

7.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

8.

Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study.

Charytan DM, Foley R, McCullough PA, Rogers JD, Zimetbaum P, Herzog CA, Tumlin JA; MiD Investigators and Committees.

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):721-34. doi: 10.2215/CJN.09350915. Epub 2016 Jan 13.

9.

A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury.

Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, Szamosfalvi B, Dev D, DaSilva JR, Astor BC, Yevzlin AS, Humes HD; SCD Investigator Group.

PLoS One. 2015 Aug 5;10(8):e0132482. doi: 10.1371/journal.pone.0132482. eCollection 2015.

10.

Major Adverse Events One Year After Acute Kidney Injury After Contrast-Enhanced Computed Tomography.

Mitchell AM, Kline JA, Jones AE, Tumlin JA.

Ann Emerg Med. 2015 Sep;66(3):267-274.e4. doi: 10.1016/j.annemergmed.2015.04.028. Epub 2015 May 23.

PMID:
26004770
11.

Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity.

Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Bennett MR, Kimmel PL, Seneff MG, Chawla LS.

J Am Soc Nephrol. 2015 Aug;26(8):2023-31. doi: 10.1681/ASN.2014060535. Epub 2015 Feb 5.

12.

The role of early and sufficient isolated venovenous ultrafiltration in heart failure patients with pulmonary and systemic congestion.

Costanzo MR, Chawla LS, Tumlin JA, Herzog CA, McCullough PA, Kellum JA, Ronco C.

Rev Cardiovasc Med. 2013;14(2-4):e123-33. Review.

PMID:
24448253
14.

Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.

Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG.

Crit Care. 2013 Sep 20;17(5):R207. doi: 10.1186/cc13015.

15.

Association of elevated urinary concentration of renin-angiotensin system components and severe AKI.

Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD, Arthur JM; SAKInet Investigators.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2043-52. doi: 10.2215/CJN.03510413. Epub 2013 Sep 5.

16.

Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery.

Arthur JM, Hill EG, Alge JL, Lewis EC, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD; SAKInet Investigators.

Kidney Int. 2014 Feb;85(2):431-8. doi: 10.1038/ki.2013.333. Epub 2013 Sep 4.

17.

Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

Tumlin JA, Costanzo MR, Chawla LS, Herzog CA, Kellum JA, McCullough PA, Ronco C.

Contrib Nephrol. 2013;182:158-73. doi: 10.1159/000349972. Epub 2013 May 13.

18.

Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

McCullough PA, Kellum JA, Haase M, Müller C, Damman K, Murray PT, Cruz D, House AA, Schmidt-Ott KM, Vescovo G, Bagshaw SM, Hoste EA, Briguori C, Braam B, Chawla LS, Costanzo MR, Tumlin JA, Herzog CA, Mehta RL, Rabb H, Shaw AD, Singbartl K, Ronco C.

Contrib Nephrol. 2013;182:82-98. doi: 10.1159/000349966. Epub 2013 May 13.

PMID:
23689657
19.

Urinary angiotensinogen and risk of severe AKI.

Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD, Arthur JM; SAKInet Investigators.

Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93. doi: 10.2215/CJN.06280612. Epub 2012 Nov 8.

20.

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA.

Clin J Am Soc Nephrol. 2013 Feb;8(2):280-9. doi: 10.2215/CJN.08230811. Epub 2012 Nov 2.

21.

The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study.

Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, DaSilva JR, Astor BC, Yevzlin AS, Humes HD.

Semin Dial. 2013 Sep-Oct;26(5):616-23. doi: 10.1111/sdi.12032. Epub 2012 Oct 29.

PMID:
23106607
22.

Prospective study of the incidence of contrast-induced nephropathy among patients evaluated for pulmonary embolism by contrast-enhanced computed tomography.

Mitchell AM, Jones AE, Tumlin JA, Kline JA.

Acad Emerg Med. 2012 Jun;19(6):618-25. doi: 10.1111/j.1553-2712.2012.01374.x.

23.

Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials.

Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA.

Clin J Am Soc Nephrol. 2012 May;7(5):851-5. doi: 10.2215/CJN.12811211. Epub 2012 Mar 22.

24.

Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings.

Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA.

Clin J Am Soc Nephrol. 2012 May;7(5):856-60. doi: 10.2215/CJN.12821211. Epub 2012 Mar 22.

25.

Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.

Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA.

Clin J Am Soc Nephrol. 2012 May;7(5):844-50. doi: 10.2215/CJN.12791211. Epub 2012 Mar 22.

26.

Immediate complications of intravenous contrast for computed tomography imaging in the outpatient setting are rare.

Mitchell AM, Jones AE, Tumlin JA, Kline JA.

Acad Emerg Med. 2011 Sep;18(9):1005-9. doi: 10.1111/j.1553-2712.2011.01152.x. Epub 2011 Aug 19.

27.

Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.

Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB.

Drug Des Devel Ther. 2011 Mar 14;5:147-53. doi: 10.2147/DDDT.S17521.

28.

Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting.

Mitchell AM, Jones AE, Tumlin JA, Kline JA.

Clin J Am Soc Nephrol. 2010 Jan;5(1):4-9. doi: 10.2215/CJN.05200709. Epub 2009 Dec 3.

29.

Prostaglandin-based renal protection against contrast-induced acute kidney injury.

McCullough PA, Tumlin JA.

Circulation. 2009 Nov 3;120(18):1749-51. doi: 10.1161/CIRCULATIONAHA.109.902189. Epub 2009 Oct 19. No abstract available.

PMID:
19841295
30.

Impaired blood flow in acute kidney injury: pathophysiology and potential efficacy of intrarenal vasodilator therapy.

Tumlin JA.

Curr Opin Crit Care. 2009 Dec;15(6):514-9. doi: 10.1097/MCC.0b013e328332f6f9. Review.

PMID:
19829105
31.

T-cell receptor-stimulated calcineurin activity is inhibited in isolated T cells from transplant patients.

Tumlin JA, Roberts BR, Kokko KE, El Minshawy O, Gooch JL.

J Pharmacol Exp Ther. 2009 Aug;330(2):602-7. doi: 10.1124/jpet.109.154096. Epub 2009 May 6.

32.

Lupus nephritis: histology, diagnosis, and treatment.

Tumlin JA.

Bull NYU Hosp Jt Dis. 2008;66(3):188-94. Review. No abstract available.

33.

Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.

Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD; LJP 394-90-09 Investigator Consortium.

Arthritis Rheum. 2008 Aug;58(8):2470-80. doi: 10.1002/art.23673.

34.

Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis.

Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, Calabrò MG, Sheiban I, Tumlin JA, Ranucci M, Zangrillo A.

J Cardiothorac Vasc Anesth. 2008 Feb;22(1):27-33. doi: 10.1053/j.jvca.2007.07.015. Epub 2007 Nov 7. Review.

PMID:
18249327
35.

A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis.

Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A.

Clin J Am Soc Nephrol. 2006 Jan;1(1):109-16. Epub 2005 Nov 30.

36.

Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options.

Tumlin JA, Madaio MP, Hennigar R.

Clin J Am Soc Nephrol. 2007 Sep;2(5):1054-61. Epub 2007 Aug 16. Review.

37.
38.

Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary.

McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ; CIN Consensus Working Panel.

Rev Cardiovasc Med. 2006 Fall;7(4):177-97.

PMID:
17224862
39.

Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, Ranucci M, Zangrillo A.

Am J Kidney Dis. 2007 Jan;49(1):56-68. Review.

PMID:
17185146
40.

Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.

Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD.

Am J Kidney Dis. 2005 Jul;46(1):26-34.

PMID:
15983954
41.
42.

Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.

Tumlin JA, Hennigar RA.

Semin Nephrol. 2004 May;24(3):256-68.

PMID:
15156530
43.

Calcineurin phosphatase activity: activation by glucocorticoids and role of intracellular calcium.

Tong DC, Buck SM, Roberts BR, Klein JD, Tumlin JA.

Transplantation. 2004 Jan 27;77(2):259-67.

PMID:
14742991
44.

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.

Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW; CONTRAST Investigators.

JAMA. 2003 Nov 5;290(17):2284-91.

PMID:
14600187
45.
46.

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B; LJP 394 Investigator Consortium.

Arthritis Rheum. 2003 Feb;48(2):442-54.

47.

Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.

Stone GW, Tumlin JA, Madyoon H, Lepor NE, McCullough PA, Mathur VS, Murray PT, O'Neill WW.

Rev Cardiovasc Med. 2001;2 Suppl 1:S31-6.

PMID:
12439366
48.
49.
50.

Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.

Tumlin JA, Dunbar LM, Oparil S, Buckalew V, Ram CV, Mathur V, Ellis D, McGuire D, Fellmann J, Luther RR.

Acad Emerg Med. 2000 Jun;7(6):653-62.

Supplemental Content

Loading ...
Support Center